Work

MA21.06 Preliminary Phase 1 Results of U3-1402 — A Novel HER3-Targeted Antibody–Drug Conjugate—in EGFR TKI-Resistant, EGFR-Mutant NSCLC

Year: 2019

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2019.08.677

Authors: H. Yu, M. Johnson, C. Steuer, M. Vigliotti, S. Chen, Y. Kamai, C. Yu, P. Jänne

Institutions: Memorial Sloan Kettering Cancer Center, Sarah Cannon, Emory University, Winship Cancer Institute, Daiichi Sankyo (United States), Daiichi-Sankyo (Japan), Dana-Farber Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2981867091

Cites:

Cited by: 2

Related to: 10